Navigation Links
Oncothyreon reports full year and fourth quarter 2007 financial results
Date:3/10/2008

could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the adequacy of financing and reserves on hand, currency exchange rate fluctuations, changes in general accounting policies, our ability to remediate an identified material weakness in our internal controls, general economic factors, achievement of the results we anticipate from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Additional Information

Additional information relating to Oncothyreon can be found on U.S. EDGAR at http://www.sec.gov and on SEDAR at http://www.sedar.com.

Oncothyreon Inc.(1)

Consolidated Statements of Operations Data

(in thousands of U.S. dollars, except share and per share data)

(unaudited)

Three Months Ended Year Ended

December 31 December 31

---------------------- ----------------------

2007 2006 2007 2006


'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
2. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
3. Oncothyreon launches new corporate website
4. Oncothyreon to present at BIO CEO & Investor Conference
5. Oncothyreon highlights corporate and clinical objectives for 2008
6. Biomira announces plan to change name to Oncothyreon
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... the first time, chemists have succeeded in measuring vibrational ... resolution. The study reveals how vibration of a single ... , The study was performed at the University ... the University of Jyvskyl works as a visiting fellow ... the study. The second team was lead by Professor ...
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized ... October 29-30 in San Francisco, CA. This year’s conference ... researchers and clinicians focused on addressing and solving the ... the twelve years since the sequencing of the human ... with pharmacogenetic information in the label and molecular diagnostics ...
(Date:8/20/2014)... Sofia, Bulgaria (PRWEB) August 20, 2014 ... was released today including improvements to the ... rates and connectors for Lucene, SOLR and Elasticsearch. ... change for this high performance triplestore – GraphDB™ ... organizations interested in deploying the only mature enterprise ...
(Date:8/19/2014)... Cellgen Diagnostics today ... fund a corporate lab for its genetic-based medical ... is a critical component in the move from ... implementation of personalized medicine – a more predictive, ... Indiegogo contributions will support Cellgen’s intent to develop ...
Breaking Biology Technology:Seeing a molecule breathe 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... ST. LOUIS, May 16 Stereotaxis, Inc. (Nasdaq:,STXS), ... Officer, will,present at the Seventh Annual JMP Securities ... 2008 at 12:00 p.m. Pacific Time., Attendance ... audio,presentation will be webcast live and remain available ...
... shown that they can use a red blood cell ... , "It turns around the rules of nanotechnology, by ... assistant professor in the Department of Biomedical Engineering at ... student Chawin Ounkomol. , An atomic force microscope uses ...
... esophagus eliminated in 90 percent ... ... Inc., the,global technology leader for treating precancerous conditions of the,digestive tract, ... study were free of the highest-risk of Barrett,s,esophagus after having a ...
Cached Biology Technology:New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 2New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 3
(Date:8/20/2014)... Cancer Institute (HCI) at the University of Utah have ... encodes BCR-ABL, the unregulated enzyme driving the blood cancer ... Society, nearly 6,000 new cases of CML will be ... tyrosine kinase inhibitors (TKIs), target BCR-ABL and are effective ... but control it in a way that allows patients ...
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
(Date:8/20/2014)... of sunscreen and seawater signals a relaxing trip to ... idyllic beach vacation comes with an environmental hitch. When ... sea, they can become toxic to some of the ... many other marine animals. Their study appears in the ... Antonio Tovar-Sanchez and David Snchez-Quiles point out that other ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
... TORONTO, ON Researchers from the University of Toronto and ... the genes in the fungus that causes Dutch Elm Disease. ... 30 million DNA letters for the fungus Ophiostoma ulmi ... online journal BMC Genomics , could help scientists figure ...
... recently voted to scrap the controversial discards policy, which ... fish waste back into the sea because they have ... could have a negative impact on some seabirds, which ... are increasingly reliant on their discards., But they say ...
... syndrome who wonder if stress aggravates their intestinal disorder, a ... all in their head. Researchers revealed that while ... and induces the intestinal inflammation that often leads to severe ... Stress has a way of suppressing an important component ...
Cached Biology News:Discards ban could impact seabird populations 2Study: Probiotics reduce stress-induced intestinal flare-ups 2
... sealed isolation chamber provides a safe, ... sterile pharmaceuticals, in accord with USP-797 ... 100 (ISO 5) cleanliness conditions in ... IV rod and tilt-up front panel ...
... siRNA Tracker Intracellular Localization Kit with ... forward approach to directly label and ... an efficient yet non-destructive manner, for ... and functional inhibition of target gene ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
Selective media for Salmonella...
Biology Products: